Thrombopoietin mimetics
AssigneeGlaxoSmithKline LLC
InventorsKevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo
Life of this patent
Estimating the term…
Abstract
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Claims14
1-50. (canceled)
A method for enhancing platelet production in a human in need thereof which method consist essentially of administering to such human a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the following formula:
- wherein Q is —COOH;
- or a pharmaceutically acceptable salt thereof.
52-53. (canceled)
(canceled)
A method for enhancing platelet production obtained from a human donor which method consist essentially of administering to such donor a pharmaceutical composition which comprises a therapeutically effective amount of the compound 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof prior to platelet pheresis, blood donation or platelet donation.
(canceled)
Dependencies are inferred from the claim text.